O Porriño, Spain, XX September 2026. Biofabri, part of the Zendal Group, has announced the completion of the vaccination stage of the Phase 3 clinical trial evaluating the tuberculosis (TB) vaccine candidate MTBVAC in newborns (MTBVACN3, NCT04975178), with 7,120 participants enrolled and vaccinated across South Africa, Senegal and Madagascar. The trial reached its target of…

The path to develop urgently needed new vaccines against tuberculosis (TB), one of the leading infectious global health threats, has gained new international momentum. The MTBVAC AVANTE consortium has officially launched its activities following the signature of a €18.2 million award from Global Health EDCTP3, the European joint undertaking for clinical trials in developing countries.